Li, "Unusual T-lymphoblastic blast phase of chronic myelogenous leukemia
," Case Reports in Hematology, vol.
Dasatinib in patients with chronic myelogenous leukemia
in lymphoid blast crisis or Philadelphia-chromosome positive acute lympho blastic leukemia who are imatinib -resistant or intolerant: the CA180015 'START-L' study.
 Nonstandard abbreviations: CML, chronic myelogenous leukemia
; TKI, tyrosine kinase inhibitor drug; BCR-ABL, fusion gene of BCR and ABL1; D-HPLC, denaturing HPLC; D-HPLC/DS, D-HPLC combined with direct sequencing; ARMS, amplification refractory mutational system; Cq, quantification cycle.
Key words: chronic myelogenous leukemia
, neoplasia, leukocytosis, avian, great horned owl, Bubo virginianus
Patients with recurrent, high-risk acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia
, many types of lymphoma, aplastic anemia, and other genetic and immunologic disorders require blood stem cell transplants to rebuild their blood supply after intense chemotherapy or as a therapeutic attack on their disease.
In addition to the cancer therapeutic PAN-622, Panacea offers: PC Detect, a diagnostic test used in conjunction with PSA and digital rectal exam to identify patients with prostate cancer; LC Detect, a diagnostic test to aide in the detection of patients with lung cancer; BC Detect, a diagnostic test to aide in the detection of recurrence of breast cancer; CC Detect, a diagnostic test to aide in the detection of colo-rectal cancer; and TK Sense, which determines whether white blood cells from patients with chronic myelogenous leukemia
(CML) are sensitive or resistant to imatinib, the therapy of first choice for CML patients, prior to initiation of therapy.
Then the Inquirer's assistant sports editor, he detailed his condition one year after being diagnosed with chronic myelogenous leukemia
Two studies at the annual meeting of the American Society of Hematology demonstrated the efficacy and safety of nilotinib in imatinib-resistant or -intolerant patients with blast-phase or chronic-phase chronic myelogenous leukemia
(CML) and in patients with acute lymphocytic leukemia (ALL) who tested positive for the Philadelphia chromosome (Ph+).
Since its introduction a few years ago, the cancer drug imatinib has given patients with chronic myelogenous leukemia
an unprecedented chance at long-term survival.
NS-187, which is a molecular targeted agent in the preclinical stage, is intended for the treatment of chronic myelogenous leukemia
In the 18th and 19th centuries, Fowler's solution (containing 1% arsenic trioxide) was prescribed to treat asthma, psoriasis, syphilis, and chronic myelogenous leukemia
(Waxman and Anderson 2001).
Referred to as a "magic cancer bullet" because of its efficacy in treating chronic myelogenous leukemia
and because patients can take it daily at home, imatinib inhibits the protein tyrosine kinases associated with the oncogene Bcr-Abl.